HC Wainwright Has Negative Outlook for Zynex Q1 Earnings

Zynex, Inc. (NASDAQ:ZYXI) – Research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Zynex in a report issued on Wednesday, March 12th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.20) per share for the quarter, down from their prior forecast of $0.07. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Zynex’s current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Zynex’s Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.40) EPS.

ZYXI has been the topic of a number of other research reports. LADENBURG THALM/SH SH downgraded Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Royal Bank of Canada lowered shares of Zynex from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $11.00 to $5.50 in a research report on Wednesday, March 12th.

Zynex Stock Performance

Shares of ZYXI stock opened at $2.97 on Monday. The stock’s 50-day moving average is $7.42 and its two-hundred day moving average is $7.91. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. Zynex has a 1 year low of $2.77 and a 1 year high of $13.19. The firm has a market cap of $94.78 million, a price-to-earnings ratio of 19.80 and a beta of 0.81.

Zynex (NASDAQ:ZYXI) last posted its earnings results on Tuesday, March 11th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11). Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company had revenue of $45.98 million during the quarter, compared to analysts’ expectations of $53.65 million. During the same period last year, the business earned $0.04 earnings per share.

Insider Activity at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $7.88, for a total transaction of $78,800.00. Following the completion of the transaction, the chief financial officer now owns 26,299 shares in the company, valued at approximately $207,236.12. This represents a 27.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $227,100 in the last quarter. Company insiders own 52.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ZYXI. Hotchkis & Wiley Capital Management LLC boosted its holdings in Zynex by 24.7% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock valued at $6,090,000 after purchasing an additional 147,770 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Zynex by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 443,020 shares of the company’s stock valued at $3,549,000 after buying an additional 17,511 shares in the last quarter. Royce & Associates LP grew its holdings in Zynex by 9.2% during the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after acquiring an additional 21,781 shares during the period. Janney Montgomery Scott LLC raised its position in Zynex by 10.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock worth $1,276,000 after acquiring an additional 14,820 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Zynex by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 137,362 shares of the company’s stock valued at $1,100,000 after acquiring an additional 3,800 shares during the period. 29.68% of the stock is currently owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.